Archive: March 03 2021
Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
Early Successes and Remaining Challenges of Harnessing Natural Killer Cells for ...
Natural killer cells can offer several advantages over T cells for CAR therapy in that the former uses both a CAR dependent and independent mechanism for tumor eradication, has better safety, and off-the-shelf feasibility—all at a potentially lower cost.
Relapsed/Refractory DLBCL Undergoes Rapid Evolution With CAR T-Cell Therapy, ADC...
High-dose chemotherapy and transplant remains the second-line standard of care for the majority of patients with relapsed/refractory diffuse large B-cell lymphoma; however, CAR T-cell therapy and other novel agents, which have transformed the third-line setting, may offer alternative and more personalized second-line options in the coming years.
Cirmtuzumab/Ibrutinib Shows Encouraging Clinical Activity, Safety in MCL and CLL
Hun Ju Lee, MD, discusses a phase 1/2 study evaluating cirmtuzumab in combination with ibrutinib in patients with mantle cell lymphoma or chronic lymphocytic leukemia.
Ianalumab/Ibrutinib Combo Shows Promising Activity in CLL
Kerry A, Rogers, MD, discusses the rationale behind the phase 1b study of VAY736 combined with ibrutinib in patients with chronic lymphocytic leukemia and the next steps for this research.
Multi-Agent Therapy May Overcome CAR T Resistance in B-Cell Malignancies
Treatment with chimeric antigen receptor T-cells has induced unprecedented overall response rates and complete response rates in patients with relapsed/refractory B cell malignancies.
Bispecific Antibodies Propel the Relapsed/Refractory Myeloma Paradigm Further Ah...
Timothy M. Schmidt, MD, discusses the integration and utility of bispecific antibodies in relapsed/refractory multiple myeloma, as well as some of the most promising agents in clinical development.
CAR-T Explodes on the Scene in Heavily Pretreated Multiple Myeloma
Binod Dhakal, MD, discusses the potential impact of ide-cel, orva-cel, and cilta-cel in multiple myeloma therapy.
Promising 5-Year Outcomes Shown With CAR T-Cell Therapy in R/R B-Cell Lymphoma
For the treatment of relapsed or refractory aggressive B-cell lymphomas, chimeric antigen receptor–modified T-cell therapy is becoming more widely used. Still, little is known about outcomes for patients who receive CAR-modified T-cell therapy beyond 2 years.
Optimizing care with CAR T-cell therapy now and in the future for patients with ...
Get an update on chimeric antigen receptor (CAR) T-cell therapy for B-cell malignancies, including guidance on referral and toxicity management, in these interviews with five experts.